| This week's sponsor is LabVantage. | | | |
Today's Rundown Publisher’s Note: FierceBiotech will not publish on Monday, Feb. 19, due to the Presidents Day holiday, but we will be back in your inbox on Tuesday, Feb. 20. Roche pens $1.9B deal to buy oncology data firm Flatiron Apricus craters as FDA rejects erectile dysfunction cream again Using stem cells to generate an immune attack against cancer Becton Dickinson sues rival Cytek Biosciences, claiming it stole trade secrets EuroBiotech Report—Boehringer failure, Roivant-Poxel, Santhera’s CF deal, CRUK and Erytech FiercePharmaAsia—Astellas acquisition, Teva’s Celltrion problem, Korea’s digital health initiative Chutes & Ladders—Axovant CEO, COO resign after disastrous readouts Featured Story | | | Friday, February 16, 2018 Roche has struck a $1.9 billion deal to acquire Flatiron Health. The takeover gives Roche ownership of the cancer software and real-world evidence that turned GV-backed Flatiron into a rising star. |
|
|
Top Stories Friday, February 16, 2018 The FDA has issued a complete response letter for Apricus’ topical erectile dysfunction drug Vitaros for the second time, sparking a massive after-hours slump in its share price. Thursday, February 15, 2018 Induced pluripotent stem cells have the power to transform into any cell in the body, making them a prime candidate for regenerative medicine. Scientists at Stanford University believe stem cells can also teach the immune system to recognize and attack cancer—and they tested the concept in mouse models of breast cancer. Friday, February 16, 2018 Becton Dickinson, a New Jersey-based medical device maker, is suing rival Cytek Biosciences and a group of former employees who jumped to Cytek, claiming they stole trade secrets. Thursday, February 15, 2018 In this week's EuroBiotech Report, Boehringer scraps its Alzheimer’s drug, Poxel lands Roivant deal, Santhera snags cystic fibrosis drug and more. Friday, February 16, 2018 Astellas pledges $102.5 million for universal donor cell company Universal Cells, approval of Teva's drugs were delayed by Celltrion's manufacturing problem, Korea plans to gather patient data for a digital health initiative. Friday, February 16, 2018 Axovant CEO David Hung and COO Marion McCourt resigned, Arcturus CSO and COO Pad Chivukula stepped down amid CEO ouster drama, Celgene stem cell spinoff emerged with Bob Hariri at the reins, plus more hirings, firings and retirings throughout the industry. Resources Presented by: Box and USDM Life Sciences Learn how biopharma and medical device companies can now collaborate on, manage and distribute regulated clinical, lab and manufacturing content in Box. That means all of your content is standardized on a single content repository that meets regulatory and compliance standards, so you can eliminate inefficient silos, enable seamless collaboration and accelerate the validation process. Sponsored by: RBC Wealth Management Employee stock option trading & administration, Restricted stock transactions (Rule 144), Affiliated trading plans (10b5-1), Directed share plans, Equity comp plan administration — private to public Presented by: Patheon Download Patheon’s whitepaper to discover two main areas where a drug developer can face significant obstacles during biologics development and how by evaluating these capabilities, it can answer the critical question of whether its in-house strategy is ready for these uncertainties. Presented by: SDC and Stiris Research What do you do when timelines are missed, data is dirty, and everyone is pointing fingers? From study delays to quality issues, sponsors can find their studies at risk with no clear solution. Watch this webinar to learn how to prevent, identify, and implement a successful clinical trial rescue. Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Presented by: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented by: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented by: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented by: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored by: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Drug Approval, Manufacturing Quality & Regulation 2018 | Online MIXiii-Biomed 2018 May 15-17, 2018 | Tel-Aviv, Israel BioBasics: Biotech for the Non-Scientist March 29-30, 2018 | Boston, MA PEGS: The Essential Protein Engineering Summit April 30-May 4 | Boston, MA Partnering for Growth 2018 March 20th | 7:30 am-6 pm
March 21st | 7:30 am-1:15 pm | 